Earnings Call Intelligence Subscribe
Home › Call Sheets › MRNA › Q2'26
Call sheet · Q2'26

Moderna (MRNA)

Q2'26 earnings call · held July 31, 2026 · compared with the Q1'26 call · management-credibility review
5/12
Disclosure score
1 high, 3 medium, 2 low flags
Financial quality
Bottom line
The sleeper story is that MRNA is structurally a $4B annual cash burn machine with 11 quarters of runway, making every binary catalyst existential. The Street sees August 5 flu PDUFA as the next leg up, but management's hedging on INT melanoma interim ('commercially valuable product maybe only in final analysis') suggests they know the hazard ratio degraded from Phase 2. The binding constraint isn't pipeline or science, it's cash runway versus time to revenue; they need INT or flu to work soon or they'll be drawing the credit facility by late 2027. Management's tell: 'We designed the study to evaluate the full commercial profile,' translation: we powered for multiple looks because we're not confident in early success. My view changes if INT interim shows HR<0.65 or flu gets premium pricing confirmed.

The 30-second version

  • MRNA quietly burning $4B cash annually while INT melanoma interim might not be as binary as Street thinks
  • The obvious flu PDUFA on August 5th masks the real story: Europe reopening in 2027
  • Norovirus vaccine failed interim efficacy, now needs fourth cohort after burning two seasons

What changed this quarter

MetricQ1'26Q2'26Change
Revenue$400M (up 300% YoY)$145M (up 2% YoY)Seasonal cliff as expected
Net Loss$1.3B GAAP ($0.5B ex-litigation)$0.8B GAAPImproved 40% sequentially
Cash & Investments$7.5B$6.9B$600M quarterly burn
R&D Expense$649M$651MFlat despite pipeline expansion
SG&A Expense$173M$216M+25% sequential increase
Cost of Sales$77M ex-litigation$93M+21% sequential, margin pressure
US Revenue Mix20% of total60% of totalGeography concentration risk rising
Cash Costs (Adjusted)$1.05B quarterly run-rate$1.0B implied Q2On track for $4B annual
Loss Per Share$3.40 GAAP$1.97 GAAPBeat by $0.16 vs prior year
Pipeline Programs9 INT studies9 INT studies + 2 new cancer programsExpanding despite cost cuts

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRNA Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.